Repertoire Immune Medicines, Inc

Seaside Therapeutics, based in Cambridge, is a pioneering leader in rare disease medicine, exemplified by its commitment to advancing the rare disease community. Ultragenyx, a subsidiary of Seaside Therapeutics, is at the forefront of driving progress in the field of rare disease treatment, dedicated to propelling the rare disease community forward. Generated from their website's infomation

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in targeted protein degradation. Their innovative approach, known as Targeted Protein Degradation (TPD), aims to develop a new generation of medicines for treating various diseases. Through their TORPEDO platform and focus on target selection, C4 Therapeutics is dedicated to transforming lives by degrading disease-causing proteins. With a strong leadership team, board of directors, and scientific advisory board, C4 Therapeutics is committed to advancing their pipeline of therapies, including CFT7455, CFT1946, and CFT8919. They also collaborate with industry partners such as Roche, Biogen, Betta Merck, and others to further their research and development efforts. At C4 Therapeutics, their values, people, and dedication to scientific progress drive their mission to revolutionize the treatment of diseases through targeted protein degradation.Generated from the website

Travere Therapeutics, based in Cambridge, is a biopharmaceutical company dedicated to identifying, developing, and providing transformative therapies for individuals affected by rare diseases. Their mission is centered on delivering life-changing treatments to improve the quality of life for those living with rare diseases, showcasing their commitment to making a meaningful impact in the healthcare industry. Generated from their website's infomation